𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis

✍ Scribed by Shinya Hayashi; Yasushi Miura; Takayuki Nishiyama; Makoto Mitani; Koji Tateishi; Yoshitada Sakai; Akira Hashiramoto; Masahiro Kurosaka; Shunichi Shiozawa; Minoru Doita


Book ID
102751743
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
576 KB
Volume
56
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

Decoy receptor 3 (DcR3), a newly identified member of the tumor necrosis factor receptor (TNFR) superfamily, is a soluble receptor that binds to members of the TNF family, including FasL, LIGHT, and TNF‐like molecule 1A. DcR3 is mostly expressed in tumor cells, and it competitively inhibits binding of TNF to TNFRs. The present study was undertaken to investigate DcR3 expression in fibroblast‐like synoviocytes (FLS) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA), and to analyze the effects of DcR3 on Fas‐induced apoptosis in RA FLS.

Methods

Expression of DcR3 in FLS was measured by reverse transcriptase–polymerase chain reaction (RT‐PCR) and Western blotting. FLS were incubated with DcR3–Fc chimera protein or transfected with DcR3 small interfering RNA (siRNA) using the lipofection method, before induction of apoptosis. Apoptosis induced by Fas in FLS was detected with TUNEL staining and Western blotting of caspase 8 and poly(ADP‐ribose) polymerase. Finally, FLS were incubated with TNFα prior to Fas‐induced apoptosis, expression of DcR3 was analyzed by quantitative RT‐PCR, and apoptosis was measured.

Results

DcR3 was expressed in both RA FLS and OA FLS. DcR3–Fc protein inhibited Fas‐induced apoptosis in FLS. Down‐regulation of DcR3 in FLS by siRNA increased Fas‐induced apoptosis. TNFα increased DcR3 expression and inhibited Fas‐induced apoptosis in RA FLS, but not in OA FLS.

Conclusion

DcR3 expressed in RA FLS is increased by TNFα and protects the cells against Fas‐induced apoptosis. These findings indicate that DcR3 may be a possible therapeutic target in RA.